tiprankstipranks
pc:troge

Trogenix

Precision Medicine
Trogenix is a pioneering biotechnology company focused on developing innovative cancer therapies through its proprietary Odysseus® platform. The company specializes in creating precision genetic medicines that target aggressive, treatment-resistant cancers by delivering potent combination payloads that kill cancer cells and stimulate the immune system, while sparing healthy tissue. Trogenix's lead program targets glioblastoma, with additional efforts in colorectal cancer liver metastases and other solid tumors, aiming to transform cancer treatment paradigms with potentially curative "one-and-done" therapies.

Leadership & Board

Currently, no data available

Latest Estimated Valuation

Estimated Valuation―
Estimated Valuation―
Total Amount Raised$70M
Total Amount Raised$70M
Total Funding Rounds1
Total Funding Rounds1
Latest Funding Amount$70M
Latest Funding Amount$70M
Latest Funding RoundSeries A
Latest Funding RoundSeries A
Post-Money Valuation―
Post-Money Valuation―

Funding Round

Funding Date
Funding Round
Amount Raised
Post-Money Valuation
Oct 08, 2025
Series A
$70.00M
―

Investors

Investor Name
Funding Round
Eli Lilly and Company
Series A
Meltwind
Series A
IQ Capital
Series A
LongeVC
Series A
Calculus Capital
Series A
National Brain Tumor Society’s Brain Tumor Investment Fund
Series A
Cancer Research Horizons
Series A

Similar Companies

A snapshot of private companies similar to Trogenix, helping you discover and navigate related company profiles.
PC:RESOLResolution Therapeutics
PC:LOQUSLoQus23 Therapeutics Ltd
PC:ILLIMIllimis Therapeutics
PC:TRELLTrellis Bioscience

Related News and Analysis

Trogenix – Weekly Recap

Trogenix – Weekly Recap

Trogenix advanced its transition into a clinical-stage oncology company this week, marking a pivotal step with the first...
4M ago
TROGE
Trogenix Doses First Patient in ADePT Trial, Advancing TGX-007 for Glioblastoma and Broader Solid Tumor Strategy

Trogenix Doses First Patient in ADePT Trial, Advancing TGX-007 for Glioblastoma and Broader Solid Tumor Strategy

New updates have been reported about Trogenix. Trogenix has started clinical dosing in its Phase I/II ADePT trial,...
4M ago
TROGE
Trogenix Doses First Patient in ADePT Trial, Advancing Gene Therapy Platform for Glioblastoma and Solid Tumors

Trogenix Doses First Patient in ADePT Trial, Advancing Gene Therapy Platform for Glioblastoma and Solid Tumors

New updates have been reported about Trogenix. Trogenix has dosed the first patient in its Phase I/II ADePT...
4M ago
TROGE
Trogenix Preclinical Breakthrough in Glioblastoma Paves Way to First-in-Human Trial

Trogenix Preclinical Breakthrough in Glioblastoma Paves Way to First-in-Human Trial

New updates have been reported about Trogenix. Trogenix has published preclinical data in Nature showing complete tumor clearance...
5M ago
TROGE
Trogenix Moves Toward Clinic After Nature Study Shows Complete Tumor Clearance in GBM Model

Trogenix Moves Toward Clinic After Nature Study Shows Complete Tumor Clearance in GBM Model

New updates have been reported about Trogenix. Trogenix Ltd is accelerating its shift into a clinical-stage oncology company...
5M ago
TROGE
Binance Highlights Growing Role of Crypto-Backed Mortgages in Traditional Finance

Binance Highlights Growing Role of Crypto-Backed Mortgages in Traditional Finance

According to a recent LinkedIn post from Binance, the company is highlighting the concept of crypto-backed mortgages as...
9h ago
BINAN
CurifyLabs Technology Deployed at High-Volume U.S. Compounding Pharmacy

CurifyLabs Technology Deployed at High-Volume U.S. Compounding Pharmacy

According to a recent LinkedIn post from CurifyLabs, the company’s technology has been adopted by Kusler’s Compounding Pharmacy...
9h ago
CURIF
Consumer Research Signals Growing Adoption of AI-Assisted Purchasing

Consumer Research Signals Growing Adoption of AI-Assisted Purchasing

According to a recent LinkedIn post from ReFiBuy, recent consumer research from Koddi and Croud points to growing...
9h ago
REFIB
JuliaHub Highlights Dyad Tool for Advanced Engineering Simulation

JuliaHub Highlights Dyad Tool for Advanced Engineering Simulation

According to a recent LinkedIn post from JuliaHub, the company is highlighting Dyad, a tool designed to convert...
9h ago
JULIA
Vals AI Positions Itself as Key Player in Independent AI Evaluation Market

Vals AI Positions Itself as Key Player in Independent AI Evaluation Market

According to a recent LinkedIn post from Vals AI, the company positions itself as addressing what it sees...
9h ago
VALSA